THE CHROMOSOME | Clinical Content Series
Subclinical Hypothyroidism
Back to Case Studies ArchiveCase Study
She was 41 years old and had been told repeatedly, across four years of annual blood tests, that her thyroid was fine. Her TSH had been sitting between 3.8 and 4.6 milliunits per litre across those four years, within the laboratory reference range of 0.4 to 5.0 that most Pakistani laboratories apply as their standard. By the criteria her physicians were using, her thyroid was functioning normally. By the criteria her body was communicating through its symptoms, something was profoundly wrong.
She had gained 14 kilograms across those four years. She was cold when everyone around her was comfortable. She was tired in the morning despite adequate sleep. Her hair was shedding more than it ever had. Her skin was dry in a way that moisturiser could not address. Her bowel had slowed, she had developed a constipation that was new, persistent, and unresponsive to dietary modification. Her periods had become heavier and more painful. Her cholesterol, which had been normal throughout her thirties, had risen substantially without any change in her diet.
Each of these symptoms had been addressed individually by different physicians. Iron supplements for the hair loss. Laxatives for the constipation. A statin for the cholesterol. Dietary advice for the weight gain. Moisturiser recommendations for the dry skin. Nobody had assembled the constellation and recognised it for what it was, the clinical signature of a thyroid gland producing insufficient hormone to meet the metabolic demands of the body it was serving, despite a TSH that remained within a laboratory reference range designed for a Western population and applied without modification to Pakistani patients whose thyroid hormone requirements and sensitivity patterns are not the same.
This is the central clinical failure of subclinical hypothyroidism management in Pakistan. The reference range is treated as the diagnostic boundary. The patient is treated as the number. And the number, a TSH between 3 and 5 that sits within normal limits on a laboratory report, tells the physician that nothing requires attention while the patient sitting across from them is experiencing every symptom of thyroid deficiency across every organ system simultaneously.
When I evaluated her comprehensively the picture confirmed what her symptoms had been communicating for four years. Her free T4 was at the very lower end of the normal range, technically normal, but at the floor of a range within which substantial metabolic consequences begin accumulating long before the formal hypothyroidism threshold is crossed. Her free T3, the active thyroid hormone that cells actually use, was suppressed below the lower limit of the normal range, reflecting the impaired T4 to T3 conversion that her elevated cortisol, insulin resistance, and visceral inflammatory load had been producing. Her thyroid peroxidase antibodies were significantly elevated, confirming an autoimmune process that her previous physicians had never tested for because her TSH had always returned within the normal range and therefore, by their diagnostic logic, no further investigation was warranted.
Her fasting insulin was elevated. Her cortisol pattern was dysregulated. Her vitamin D was severely deficient. Her inflammatory markers were raised. Every one of these findings was both a consequence of her subclinical thyroid deficiency and a driver of it, each one impairing thyroid function further while the thyroid deficiency worsened each of them in return.
The FTO gene's relationship with subclinical hypothyroidism in Pakistani patients is one of the most clinically important and most consistently overlooked aspects of Pakistani thyroid medicine. The FTO associated metabolic profile creates a predisposition to hypothalamic pituitary thyroid axis dysregulation that produces meaningful thyroid hormone deficiency at TSH levels that Western reference ranges classify as entirely normal. Pakistani patients with the FTO associated metabolic profile experience the metabolic consequences of thyroid deficiency, weight gain, cold intolerance, fatigue, dyslipidaemia, cognitive slowing, at TSH levels between 2.5 and 5.0 that their physicians dismiss as unremarkable. The reference range was not designed for them. It was designed for a Western population with a different genetic background and a different metabolic predisposition, and its uncritical application to Pakistani patients produces systematic underdiagnosis of a condition that is driving weight gain, cardiovascular risk, and metabolic deterioration in a substantial proportion of the Pakistani population.
We treated the patient rather than the reference range. We addressed her subclinical hypothyroidism with thyroid hormone support calibrated to her symptoms, her free T3 level, and her metabolic picture rather than to her TSH alone. We treated her Hashimoto's autoimmune process, reducing the inflammatory assault driving her thyroid dysfunction and preventing its progressive worsening. We addressed her insulin resistance, removing the T4 to T3 conversion impairment that had been leaving her cells functionally thyroid deficient even on the limited thyroid hormone support her gland was providing. We corrected her vitamin D deficiency. We recalibrated her cortisol pattern, removing the cortisol mediated T4 to T3 conversion suppression that had been deepening her functional thyroid deficiency from the metabolic side. We reduced her visceral inflammatory load.
Thirteen months later her free T3 had normalised. Her thyroid antibodies had fallen by more than half. She had lost 16 kilograms. Her cholesterol had returned to normal without the statin that had been prescribed for what was fundamentally a thyroid driven lipid abnormality. Her hair shedding had resolved. Her bowel had normalised. Her energy had returned to a level she had not experienced since her mid thirties.
She had not had a normal thyroid for four years. She had had a TSH within a reference range that was never designed for her, and the difference between those two statements is the difference between four years of progressive metabolic deterioration and the treatment that reversed it in thirteen months.
FAQs
Subclinical hypothyroidism is defined as a TSH elevated above the upper limit of the reference range with normal free thyroid hormone levels, but this definition applies a Western derived reference range to a Pakistani population with a different genetic metabolic background and different thyroid hormone sensitivity patterns. Research increasingly supports that Pakistani and South Asian patients experience clinically significant thyroid deficiency symptoms and metabolic consequences at TSH levels between 2.5 and 5.0 that conventional Pakistani laboratory ranges classify as normal. Dr. Zaar evaluates thyroid function through the complete clinical and metabolic picture, symptoms, free T3 and T4 levels, antibody status, and metabolic markers, rather than through TSH alone against a reference range designed for a population that is not Pakistani.
Even modest thyroid hormone deficiency reduces the metabolic rate of every cell in the body simultaneously, slowing fat oxidation, reducing thermogenesis, impairing gut motility, reducing cardiac output, and decreasing the energy available for every metabolic process. In Pakistani patients, the FTO associated predisposition to insulin resistance amplifies these metabolic consequences, because thyroid hormone is required for normal insulin signalling, and its deficiency deepens insulin resistance while insulin resistance simultaneously impairs thyroid hormone conversion from inactive T4 to active T3. The result is a bidirectional metabolic suppression in which subclinical thyroid deficiency and insulin resistance compound each other progressively, producing weight gain, fatigue, dyslipidaemia, and cognitive slowing that accelerates with every year of inadequate treatment.
The FTO gene at Chromosome 16q12.2 influences hypothalamic pituitary thyroid axis sensitivity, the system through which the brain calibrates thyroid stimulating hormone output in response to circulating thyroid hormone levels. In Pakistani patients, the FTO associated metabolic profile creates a predisposition to thyroid axis dysregulation in which meaningful thyroid hormone deficiency develops and produces metabolic consequences at TSH levels that fall within the conventional normal range. Simultaneously, the FTO associated visceral fat accumulation generates the chronic inflammatory cytokine environment that impairs thyroid hormone receptor sensitivity at the cellular level, producing a functional thyroid hormone deficiency even when circulating hormone levels appear adequate on standard testing. Dr. Zaar identifies this genetic amplification of thyroid sensitivity as a core component of subclinical hypothyroidism assessment in Pakistani patients.
TSH measures the pituitary's assessment of thyroid hormone adequacy, it is an indirect measure of thyroid function one hormonal step removed from the actual hormone that cells use. Free T3 is the biologically active thyroid hormone that enters cells and drives metabolic activity, it is the hormone that matters at the cellular level where metabolic consequences are produced. In Pakistani obesity patients, the conversion of T4 to active T3 is impaired by multiple simultaneous drivers, elevated cortisol, insulin resistance, visceral inflammation, selenium deficiency, and fasting stress, producing a state in which TSH and T4 appear adequate while free T3 is suppressed and cells are functionally thyroid deficient. Measuring TSH without free T3 in Pakistani obesity patients is measuring the wrong number, it assesses the signal without assessing whether the signal is being effectively translated into the hormone that actually matters.
Even subclinical thyroid deficiency produces a cardiovascular risk profile that is clinically significant and consistently underestimated in Pakistani medicine. Thyroid hormone deficiency elevates total cholesterol and LDL cholesterol, because thyroid hormone is required for the hepatic LDL receptor activity that clears cholesterol from the bloodstream. It raises triglycerides, reduces HDL cholesterol, impairs endothelial function, increases arterial stiffness, and reduces cardiac contractility. In Pakistani patients with the FTO associated predisposition to cardiovascular risk, these thyroid driven cardiovascular effects add a substantial additional burden to an already compromised vascular risk profile. Pakistani patients prescribed statins for dyslipidaemia without thyroid assessment are being treated for a metabolic consequence, elevated cholesterol, without addressing its hormonal cause, thyroid deficiency, and the statin does not treat what the thyroid is producing.
Cortisol suppresses the enzyme deiodinase, specifically the type 1 and type 2 deiodinase enzymes responsible for converting inactive T4 to active T3 in peripheral tissues and within the pituitary gland itself. When cortisol is chronically elevated, as it consistently is in Pakistani patients with the stress burden, sleep disruption, and visceral inflammatory load of urban professional life, deiodinase activity is suppressed and T4 to T3 conversion is reduced regardless of how much T4 the thyroid is producing. The result is a pattern of normal T4 with suppressed free T3 that represents functional thyroid hormone deficiency at the cellular level while appearing adequately treated on standard thyroid panels. This cortisol mediated conversion impairment is one of the most important and most consistently missed drivers of subclinical hypothyroidism in Pakistani patients, and it resolves when cortisol is treated, not when thyroid medication is increased.
Thyroid hormone is essential for normal neurological function, it regulates neurotransmitter synthesis and activity, supports myelin integrity throughout the nervous system, governs the speed of neural transmission, and maintains the serotonergic and dopaminergic tone that underpins mood, motivation, and cognitive performance. Even modest thyroid deficiency produces measurable cognitive slowing, reduced processing speed, impaired working memory, decreased concentration, and the motivational flatness that Pakistani patients describe as their mind not working as it should. The mood consequences, low mood, anxiety, emotional flatness, and the anhedonia of reduced dopaminergic tone, are almost universally attributed to psychological causes in Pakistani clinical practice and managed with antidepressants that provide symptomatic relief without addressing the thyroid deficiency driving the neurological consequences. Treating the thyroid resolves the mood and cognitive symptoms at their biological origin.
Standard Pakistani thyroid management applies a binary diagnostic framework, TSH within range means no treatment, TSH above range means levothyroxine, without evaluating free T3, thyroid antibodies, conversion efficiency, or the metabolic and hormonal drivers of thyroid dysfunction. THE CHROMOSOME protocol evaluates the complete thyroid picture, TSH, free T4, free T3, reverse T3, thyroid antibodies, iodine status, selenium status, vitamin D, cortisol pattern, insulin resistance, and visceral inflammatory load, treating every driver of thyroid dysfunction simultaneously rather than addressing the TSH number in isolation. Thyroid hormone support, where indicated, is calibrated to free T3 normalisation and symptom resolution rather than to TSH suppression. And the autoimmune process driving the dysfunction is treated directly, because correcting the number without addressing the biological process producing the abnormality is management, not medicine.